NCT02675660已完成1 期
Study to Evaluate the Safety, Tolerability, Kinetics, and Dynamics of Single and Multiple Doses of an Oral Formulation of L-Homoarginine
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- Area under the plasma concentration versus time curve (AUC)
研究概览
简要总结
This study represents an initial clinical evaluation of an oral formulation of L-homoarginine. L-homoarginine and L-arginine are amino acids found in food proteins and are both substrates for nitric oxide synthase (NOS). L-arginine is available as over the counter nutraceutical. This study will provide information on the dosing of L-homoarginine in order to reach high physiological plasma concentrations in humans.
详细描述
- Study Design In a randomized, double-blind, placebo-controlled cross-over design participants receive either L-homoarginine 125 mg or placebo once daily in the morning for four weeks each. The study periods are separated by a washout phase of four weeks, and the sequence of the medications is randomly chosen in each participant. The study is preceded by a run-in phase, where all participant receive a single dose of 125 mg L-homoarginine. Blood samples (2.7 ml ethylenediaminetetraacetic acid vacutainer) for plasma L-homoarginine determinations are drawn at time points 0, 15 min, 30 min, 1, 2, 4, 8, 24, 48, 72, and 120 hours after single and multiple doses of L-homoarginine and placebo, respectively. At baseline and four weeks after each supplementation period (hArg and placebo), routine laboratory, arginine, asymmetric dimethylarginine, pulse wave velocity, augmentation index, flow-mediated vasodilatation, transcranial magnetic stimulation, and test battery of attentional performance are evaluated as secondary endpoints.
- Study Duration One year
- Sample Size Calculation and Statistical Evaluation Due to the exploratory nature of this pilot study, exploratory statistical methods will be used for statistical evaluation of the study results, and no formal sample size calculation was performed. In a previous study 20 participants were included to assess the kinetic, dynamic, and safety profile of L-citrulline and L-arginine [Schwedhelm et al. 2007]. Statistical comparisons will be performed using two-sided tests, i.e. Student's t-test and ANOVA. A p < 0.05 will be considered significant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, 20-75 years of age on the day of dosing and is generally healthy as determined by medical history, physical examination, and laboratory test values
- •For females, postmenopausal for at least 2 years prior to screening (confirmed by a negative hormone panel, i.e., plasma 17β-estradiol concentration of <20 pg/mL and follicle-stimulating hormone level of >40 IU/mL) or contraception
- •Has signed and received a copy of the written informed consent form approved by the investigator's Independent Ethics Committee (IEC), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by the study protocol
排除标准
- •Sitting blood pressure greater than 160/100 or less than 90/60 mm Hg
- •Sitting heart rate greater than 99 bpm or less than 50 beats per minute (bpm)
- •History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness
- •Body Mass Index (BMI) greater than 32 or less than 16 at screening [BMI = Weight (kg) ÷ Height2 (m2)]
- •History or symptoms of cardiovascular disease, particularly coronary artery disease, arrhythmias,or congestive heart failure
- •History of significant central nervous system disease, including transient ischemic attack, stroke, seizure disorder, or behavioral disturbances
研究组 & 干预措施
L-Homoarginine
Experimental
125 mg of L-homoarginine
干预措施: L-Homoarginine (Dietary Supplement)
Placebo
Placebo Comparator
placebo capsules
干预措施: Placebo (Drug)
结局指标
主要结局
Area under the plasma concentration versus time curve (AUC)
时间窗: 1 Month
To determine the AUC of L-homoarginine (a) following a single oral dose and (b) following administration of multiple oral doses of L-homoarginine.
次要结局
- Peak plasma concentration (Cmax)(1 Month)
- Half life of plasma concentration (t1/2)(1 Month)
研究者
相似试验
撤回
1 期
3D011-08 Monotherapy in Subjects With Advanced Solid TumorsSolid Tumor, AdultNCT050995363D Medicines (Beijing) Co., Ltd.
终止
1 期
Study of LUCAR-20S in Patients With R/R NHLDiffuse Large B Cell LymphomaSmall Lymphocytic LymphomaMantle Cell LymphomaFollicular LymphomaNCT04176913The First Affiliated Hospital with Nanjing Medical University7
招募中
1 期
A Study of FZ-AD005 in Patients With Advanced Solid TumorsAdvanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)NCT06424665Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.162
已完成
1 期
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941Liver DiseaseNCT01187186Astellas Pharma Inc16
进行中（未招募）
1 期
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesNon Hodgkin LymphomaChronic Lymphocytic LeukemiaNCT03913949Ascentage Pharma Group Inc.74